The first function of Core B is to provide a systematic and reliable mechanism for the handling, storage, and distribution of tumor and blood specimens from patients and family members. A neuropathologist is available to immediately examine, divide, and distribute all tissue samples derived from the neurosurgical procedures performed on site. Tissue will be used for diagnosis, for short-term cell culture, frozen for molecular studies by the various projects, and stored for preparation of frozen sections. Information concerning diagnosis, origin, and distribution of the tissue will be recorded in a computer database to facilitate retrieval and tracking. These activities will be performed by neuropathologists and by the histotechnicians and research assistants under their direct supervision. A second function of Core B is to perform frozen or paraffin sectioning of the stored tissue for the various projects and to centralize the performance of any in situ labeling studies, such as immunohistochemistry, using the several markers described in the individual projects and in the Core. Data will be recorded and returned to the initiating project for analysis. This area will include examination of frozen sections for selection of appropriate tissue for use by the other projects in molecular studies. It will also include examination of stained sections for diagnosis of tumor samples for referred patients, selection and requesting of tissue blocks for subsequent study. The neuropathologists will supervise and perform these studies. A third function will be performance of RNA isolation and cDNA construction by the Core for distribution to other projects and for use in sequencing studies to support Project 6. These activities will be performed by research technicians jointly supervised by Drs. Bruner and Kyritsis. Our ability to centralize and monitor these vital Core functions, including collection, use, and distribution of primary brain tumor specimens and blood samples, provides an essential resource for coordination of the tissue and molecular studies of this Program Project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055261-05
Application #
6237241
Study Section
Project Start
1997-02-17
Project End
1998-01-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Liu, Yanhong; Shete, Sanjay; Hosking, Fay et al. (2010) Genetic advances in glioma: susceptibility genes and networks. Curr Opin Genet Dev 20:239-44
Puduvalli, V K; Sampath, D; Bruner, J M et al. (2005) TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 10:233-43
Levin, Victor A; Hess, Kenneth R; Choucair, Ali et al. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981-90
Puduvalli, Vinay K; Hashmi, Masood; McAllister, Leslie D et al. (2003) Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival. Oncology 65:259-66
Wrensch, Margaret; Minn, Yuriko; Chew, Terri et al. (2002) Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 4:278-99
Berrak, Su Gulsun; Ozek, Memet M; Canpolat, Cengiz et al. (2002) Association between DNA content and tumor suppressor gene expression and aggressiveness of atypical teratoid/rhabdoid tumors. Childs Nerv Syst 18:485-91
de Andrade, M; Barnholtz, J S; Amos, C I et al. (2001) Segregation analysis of cancer in families of glioma patients. Genet Epidemiol 20:258-70
Davies, M A; Koul, D; Dhesi, H et al. (1999) Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res 59:2551-6
Sano, T; Lin, H; Chen, X et al. (1999) Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59:1820-4
Levin, V A (1999) Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro Oncol 1:69-80

Showing the most recent 10 out of 36 publications